Trials / Unknown
UnknownNCT02749513
Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Dallas VA Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itraconazole |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2019-09-01
- Completion
- 2022-10-01
- First posted
- 2016-04-25
- Last updated
- 2021-11-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02749513. Inclusion in this directory is not an endorsement.